Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

Overview of attention for article published in International Journal of Retina and Vitreous , March 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 22 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 2,399 followers.

¡¡Buenas noticias!!

20 Apr 2021

Reply Repost Favourite

RT @AnxoFF: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketin…

20 Apr 2021

Reply Repost Favourite

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study https://t.co/aylEdpe2k8

20 Apr 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.